Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

Rifadin

Subpotent drug: low fill volume in some of the capsules

Terminated Wrong potency / content Sanofi US NDC 0068-0510-30 D-841-2013
Class II · Moderate risk

Venlafaxine Hydrochloride Tablets

Failed Tablet/Capsule Specifications: Pharmacist complaint of an excessive amount of broken and/or chipped tablets in the bottle.

Terminated Failed specification Zydus Pharmaceuticals USA Inc NDC 68382-021-01 D-202-2013
Class II · Moderate risk

FREPP/SEPP Kit containing 1 FREPP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-202-99 D-229-2013
Class II · Moderate risk

Donor Prep Kit containing 1 FREPP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-201-99 D-228-2013
Class II · Moderate risk

Blood Culture Prep Kit II containing 1 FREPP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-200-99 D-227-2013
Class II · Moderate risk

SEPP 10% Povidone Iodine Solution USP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-145-01 D-226-2013
Class II · Moderate risk

SEPP 2% Iodine Tincture USP

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-161-01 D-225-2013
Class II · Moderate risk

SEPP 70% Isopropanol

Labeling: Not Elsewhere Classified: This product is misbranded because the product is not sterile and the labeling is misleading in relation to sterility claims.

Terminated Labeling / mix-up CareFusion 213, LLC NDC 54365-170-01 D-224-2013
Class II · Moderate risk

0.9% Sodium Chloride Injection

Labeling Wrong Barcode; It may display wrong product code reflecting 0.9% Sodium Chloride Injection , USP 100 mL in MINI-BAG Plus container instead of 50 mL.

Terminated Labeling / mix-up Baxter Healthcare Corp. NDC 0338-0553-11 D-623-2013
Class II · Moderate risk

Rifadin (rifampin)

Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.

Terminated Wrong potency / content Sanofi-Synthelabo D-886-2013
Class II · Moderate risk

Cefdinir for Oral Suspension

Defective Container: This recall is being carried out due to the potential for improperly sealed bottles.

Terminated Packaging defect Teva Pharmaceuticals USA, Inc. NDC 0093-4136-64 D-247-2013
Class II · Moderate risk

Propofol Injectable Emulsion

Presence of Particulate Matter: Visible particulate embedded in vials was observed and confirmed in a sample bottle during retain inspection.

Terminated Particulate / foreign matter Hospira Inc. NDC 0409-4699-30 D-223-2013
Class II · Moderate risk

0.9% Sodium Chloride Injection

Lack of Assurance of Sterility: The product is being recall due to the product lot being incorrectly released without meeting product specifications. There is the potential for the solution to leak from the administrative port to the fill tube seal.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7984-36 D-243-2013
Class II · Moderate risk

Amoxicillin for Oral Suspension

Microbial Contamination of Non-Sterile Products: Suspensions made from these lots of Amoxicillin 125 mg/5 mL showed yeast and mold growth at the 14 day time point.

Terminated Microbial contamination Dr Reddys Laboratories Tennessee LLC NDC 43598-222-80 D-239-2013
Class II · Moderate risk

METRONIDazole Injection

Lack of Assurance of Sterility: There is the potential for the solution to leak from the administrative port to the fill tube seal.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7811-24 D-206-2013
Class II · Moderate risk

0.9% Sodium Chloride Irrigation

Lack of Assurance of Sterility: There is a potential for the solution to leak from the administration port of the primary container.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7972-08 D-176-2013

Recalls by year